Intellia Therapeutics Management
Management criteria checks 2/4
Intellia Therapeutics' CEO is John Leonard, appointed in Jan 2018, has a tenure of 6.25 years. total yearly compensation is $10.10M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth $22.21M. The average tenure of the management team and the board of directors is 5.2 years and 9 years respectively.
Key information
John Leonard
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 6.2% |
| CEO tenure | 6.3yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.2yrs |
| Board average tenure | 9yrs |
Recent management updates
Recent updates
Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24
Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
Aug 01Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Jul 05Intellia Makes History. Can It Deliver A Cure?
Jun 28Intellia Therapeutics Q1 2021 Earnings Preview
May 05Intellia Expands Its In Vivo Advantage
May 02Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth
Apr 16Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher
Mar 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$481m |
| Sep 30 2023 | n/a | n/a | -US$462m |
| Jun 30 2023 | n/a | n/a | -US$453m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$10m | US$630k | -US$474m |
| Sep 30 2022 | n/a | n/a | -US$442m |
| Jun 30 2022 | n/a | n/a | -US$400m |
| Mar 31 2022 | n/a | n/a | -US$369m |
| Dec 31 2021 | US$10m | US$600k | -US$268m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$185m |
| Mar 31 2021 | n/a | n/a | -US$149m |
| Dec 31 2020 | US$4m | US$580k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$120m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$109m |
| Dec 31 2019 | US$904k | US$559k | -US$100m |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | US$10m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$83m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$3m | US$396k | -US$68m |
Compensation vs Market: John's total compensation ($USD10.10M) is above average for companies of similar size in the US market ($USD5.42M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Leonard (66 yo)
6.3yrs
Tenure
US$10,096,590
Compensation
Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.3yrs | US$10.10m | 1.06% $ 22.2m | |
| Executive VP | 5.5yrs | US$3.43m | 0.072% $ 1.5m | |
| Executive VP & Chief Scientific Officer | 4.9yrs | US$3.72m | 0.085% $ 1.8m | |
| Executive VP | 2.8yrs | US$3.63m | 0.085% $ 1.8m | |
| Executive VP & Chief Medical Officer | 4yrs | US$3.72m | 0.097% $ 2.0m | |
| Executive VP & Chief Business Officer | 2.3yrs | US$5.08m | 0.069% $ 1.4m | |
| Founder & Member of Scientific Advisor Board | 9.9yrs | US$11.27m | no data | |
| Co-Founder | 9.9yrs | US$311.57k | no data | |
| Founder and Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data |
5.2yrs
Average Tenure
57yo
Average Age
Experienced Management: NTLA's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 9.8yrs | US$10.10m | 1.06% $ 22.2m | |
| Founder & Member of Scientific Advisor Board | no data | US$11.27m | no data | |
| Founder and Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | 9yrs | no data | no data | |
| Founder & Member of Scientific Advisor Board | 9yrs | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Founder & Member of Scientific Advisor Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data | |
| Independent Chairman of the Board | 6.8yrs | US$495.80k | 0.0076% $ 159.1k | |
| Independent Director | less than a year | no data | 0.0071% $ 148.4k |
9.0yrs
Average Tenure
60yo
Average Age
Experienced Board: NTLA's board of directors are considered experienced (9 years average tenure).